Key Takeaways GSK's Nucala gained EU nod as an add-on maintenance treatment for certain COPD patients.Phase III MATINEE data showed Nucala reduced moderate/severe COPD exacerbations versus placebo.GSK's Nucala is the first and only biologic in the EU for COPD patients with an eosinophilic phenotype.GSK plc (GSK) announced that the European Commission has approved its blockbuster respiratory drug, Nucala (mepolizumab), for treating certain patients with chronic obstructive pulmonary disease (COPD), marking a ...

Hey. Hello and welcome to a bonus episode of the Morning Filter podcast. I'm Susan Jabinsky.Now, my co-host Dave Sakara and I have gotten a lot of questions from our audience about topics you'd like to hear more about, and we hear you. So, we're doing some bonus episodes of the podcast, sitting down with various Morning Star experts to discuss topics that you want to hear more about. If you have an idea for a bonus episode, you can send it to us at our email address, which is the morning filter@ morningstar ...

受理号JYHZ2600018药品名称盐酸帕罗西汀肠溶缓释片药品类型化药申请类型进口再注册注册分类无企 业名称GLAXOSMITHKLINE INC.;BORA PHARMACEUTICAL SERVICES INC.;GlaxoSmithKline(China) Investment Company Limited;承办日期2026年2月5日 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 来源：新浪财经-鹰眼工作室 国家药品监督管理局药品审评中心数据显示，2026年2月5日，GLAXOSMITHKLINE INC.的盐酸帕罗西 汀肠溶缓释片申请已获受理，受理号为JYHZ2600018。 ...

GSK Stock Soars To 12-Year High On Bullish Views That Have Nothing To Do With Obesity | Investor's Business DailyTRENDING: [How To Handle The Current Market]---GSK (GSK) stock catapulted to a 12-year high Wednesday after the U.K.-based drugmaker said it expects sales in five years' time to approach $55 billion. This will come despite not having a GLP-1 drug in the red-hot weight-loss space. "I think it's going to be very crowded," Chief Executive Luke Miels told reporters early Wednesday, according to BioSp ...

英国制药巨头葛兰素史克(GSK.US)涨超7%，最高触及57.34美元，创下历史新高。消息面上，葛兰素史 克去年总营收同比增长4%至326.7亿英镑，超过分析师预期的325亿英镑；归属于股东的净利润同比大 幅增长121.7%至57.2亿英镑，合每股收益1.388英镑。期内，专科药物销售额同比增长17%，达到134.7 亿英镑，主要得益于HIV药物需求强劲。董事会宣布派发季度股息每股0.18英镑，使得2025年全年股息 达到每股0.66英镑，高于2024年的每股0.61英镑。(格隆汇) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2026 Commission File Number 001-15170 GSK plc (Translation of registrant's name into English) 79 New Oxford Street, London, WC1A 1DG (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form ...

Core Insights - GSK plc reported fourth-quarter 2025 core earnings of 68 cents per American depositary share (ADS), exceeding the Zacks Consensus Estimate of 64 cents, with a 10% year-over-year increase on a reported basis and 14% at a constant exchange rate (CER) [1][9] - Quarterly revenues rose 6% on a reported basis and 8% at CER to $11.46 billion (£8.62 billion), driven by increased sales of HIV, oncology, and respiratory medicines, surpassing the Zacks Consensus Estimate of $11.19 billion [2][9] Segment Performance - GSK operates under three segments: General Medicines, Specialty Medicines, and Vaccines. Specialty Medicines sales increased by 18%, while Vaccine sales rose by 4%. General Medicines sales fell by 1% [3] - Specialty Medicines drove top-line growth, with HIV sales up 11% due to increased demand for Dovato and long-acting medications like Apretude and Cabenuva [4][5] - Oncology sales surged by 42%, primarily due to strong demand for Jemperli and Ojjaara/Omjjara, with Jemperli sales increasing by 79% following label expansion [6][7] - Respiratory drug Nucala sales rose by 19%, driven by strong performance in the U.S. market, while Benlysta sales increased by 26% [8] Vaccine Sales - GSK's vaccine sales growth was driven by increased uptake of meningitis, RSV, and shingles vaccines in ex-U.S. markets, with Shingrix sales rising by 20% [10] - Established vaccine sales declined by 13% due to divested brands and lower sales for Rotarix and Synflorix [11] General Medicines - General Medicines showed stable performance with Trelegy Ellipta sales up 14%, while Anoro Ellipta and Relvar/Breo Ellipta sales fell by 10% and 16%, respectively [12][13] Operating Expenses and Guidance - Core selling, general, and administration costs rose by 2% to £2.68 billion, while core research and development expenses increased by 18% to £2.12 billion [14] - GSK expects sales growth of 3-5% in 2026, with specialty medicines projected to grow by a low double-digit percentage at CER [15] Future Outlook - GSK has a total of 58 assets in clinical development, with two major product approvals expected this year [21][22] - The company aims to generate sales of more than £40 billion by 2031, reflecting a positive long-term outlook [18]

GSK (GSK) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +6.25%. A quarter ago, it was expected that this drug developer would post earnings of $1.26 per share when it actually produced earnings of $1.48, delivering a surprise of +17.46%.Over the last four quarters, the company has s ...

该公司还维持了今年利润增长7%至9%的指引。部分分析师此前预计的指引约为每股收益增长 6%至8%，新任首席执行官卢克·米尔斯为这一年设定了一个可能被超越的目标，其中抗癌药物 Blenrep有望提振收入。 葛兰素史克预计 2026 年营业额增长 3% 至 5%；核心营业利润增长 7% 至 9%；核心每股收 益增长 7% 至 9%。该公司预计到 2031 年销售额将超过 400 亿英镑。 葛兰素史克(GSK.US) 第四季度利润高于预期，这主要得益于其艾滋病(HIV)药物以及一款现已获批用 于治疗肺部疾病的哮喘药物。财报显示，葛兰素史克四季度营收达 86.2 亿英镑，同比增长 6.3%，超 出预期 1.7 亿英镑；调整后每股收益为 25.5 便士(约合 35 美分)，高于分析师的预期。 该公司经营活动产生的现金流为 89 亿英镑，自由现金流为 40 亿英镑。 在前CEO沃尔姆斯利执掌期间，葛兰素史克拆分了其消费者健康部门 Haleon，并进行了关键收 购以尝试增强其药物研发管线。尽管如此，米尔斯仍需向投资者证明，公司能够实现本十年末及 更长远时期的营收抱负。上个月，葛兰素史克同意以 22 亿美元的交易价格收购总部 ...

On cash flow and capital allocation, Brown said free cash flow rose to £4.0 billion (more than £5.0 billion excluding Zantac payments). Zantac payments in 2025 were £1.2 billion, bringing total payments to £1.9 billion, with the settlement process described as “materially complete.” She added that shareholder distributions totaled £4.0 billion via dividends and buybacks, including repurchase of 93 million shares at an average price of 1,473 (with the remaining £0.6 billion to be completed in the first half) ...